Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02371941 · ClinicalTrials.gov registry record · Phase 4

Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis

A Phase 4 study of Eosinophilic Esophagitis, sponsored by University of Tennessee.

Completed
Registry status
Phase 4
Development phase
16
Enrollment target
1
Study location

NCT02371941 is a Phase 4 study of Eosinophilic Esophagitis that has completed, run by University of Tennessee. The registered enrollment target is 16 participants, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02371941, a Phase 4 study of Eosinophilic Esophagitis, has completed, sponsored by University of Tennessee.

COMPLETED
Registry status
Phase 4
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

This is a randomized, double-blind, placebo-controlled study of oral cromolyn sodium when made into a viscous preparation for the treatment of eosinophilic esophagitis.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG oral cromolyn sodium

Study Locations (1)

Tennessee

  • LeBonheur Children's Hospital - Memphis

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2014-12
Est. Completion 2017-12
Phase Phase 4

Sponsor

University of Tennessee

96 total trials

What the Registry Record Tells You About NCT02371941

The ClinicalTrials.gov registry entry for NCT02371941 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (98% lower). The listed sponsor is University of Tennessee, which has 96 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02371941 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT02371941 about?

NCT02371941 is a clinical study titled "Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis". This is a randomized, double-blind, placebo-controlled study of oral cromolyn sodium when made into a viscous preparation for the treatment of eosinophilic esophagitis.

What is the current status of trial NCT02371941?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2014-12. Estimated completion is 2017-12.

What conditions does trial NCT02371941 study?

This clinical trial studies the following conditions: Eosinophilic Esophagitis.

What interventions are being tested in trial NCT02371941?

The interventions under investigation include: Placebo (DRUG), oral cromolyn sodium (DRUG).

Who is sponsoring clinical trial NCT02371941?

This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02371941 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Eosinophilic Esophagitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.